PCP
EGRX

Proficio Capital Partners’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Proficio Capital Partners’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-149
Closed -$8K – 1635
2019
Q2 		$8K Sell
149
-29
-16% -$1.51K ﹤0.01% 1049
2019
Q1 		$9K Buy
+178
New +$7.92K ﹤0.01% 926

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Proficio Capital Partners's EGRX Position: Q3 2019 in Review

Proficio Capital Partners sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2019, closing a stake of 149 shares — an estimated $8K sold.

Proficio Capital Partners first reported a position in EGRX in Q1 2019 and held it in 2 quarters. The position peaked at $9K in Q1 2019. 183 funds tracked by Wall St. Rank hold EGRX as of Q3 2019.

  • Proficio Capital Partners reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
  • Proficio Capital Partners sold 149 Eagle Pharmaceuticals, Inc. shares in Q3 2019, an estimated $8K.
  • Proficio Capital Partners first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2019 and held it in 2 quarters.
  • Proficio Capital Partners's Eagle Pharmaceuticals, Inc. position peaked at $9K in Q1 2019.
  • 183 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2019.

Based on Proficio Capital Partners's 13F filing for Q3 2019, filed 13 Nov 2019.